As you can imagine, The Jerusalem Post is read by more people than ever before.
However, traditional business models are no longer sustainable and are high quality publications,
as ours, are forced to seek new ways of continuing. Unlike many other news organizations,
we have not set a pay wall. We want to keep our journalism open
and accessible and able to continue to give you news
and an analysis of the front line of Israel, the Middle East and the Jewish World.
As one of our loyal readers, we ask you to be our partner.
For $ 5 a month you will have access to the following:
- User experience is almost completely free of ads
- Access to our Premium Department
- Contents of the award-winning Jerusalem Report and our monthly magazine to teach Hebrew – Ivrit
- A brand new email includes the daily newspaper as it appears in print in Israel
Help us to grow and continue to tell the story of Israel to the world.
Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Chief Editor
UPDATE YOUR JPOST EXPERIENCE FOR 5 $ FIS
Show me later
TEL AVIV – CollPlant, which makes products for tissue repair and organ manufacture into a recombinant human collagen, has launched a new research and development center in Israel.
The facilities will serve CollPlant for developing its products, including BioInks for 3D bioprint tissues and organs, and dermal fillings for medical aesthetics, said the company on Wednesday.
Collagen is a protein found in tissues such as tendons, skin, blood vessels and bones. CollPlant produces collagen from tobacco plants that have been genetically engineered with five human genes. Its first products approved for sale in Europe are used for tendonitis and wound care.
He will try to commercialize these products in the US, says Chairman Jonathan Rigby, adding: “We expect to secure more partnerships in the future.”
CollPlant also works on dermal fillings to inject into the wrinkles. Although existing fillers erode over time, the effects of human collagen are much longer, he told Reuters. The company expects approval for this product in 3 to 5 years.
In 2018, CollPlant signed an agreement with United Therapeutics Corp for the use of CollInland's BioInk for 3D bioprint of lung scaffolding with a long-term goal of transplanting lungs, subject to U regulatory approval.
Join Jerusalem Post Premium Plus now for just $ 5 and upgrade your experience with a non-advertisement website and unique content. Click here >>